StockNews.com Downgrades DexCom (NASDAQ:DXCM) to Hold

DexCom (NASDAQ:DXCM) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

Several other analysts have also weighed in on DXCM. Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $141.40.

DexCom Trading Up 2.9 %

DXCM opened at $137.87 on Tuesday. The firm has a market cap of $53.15 billion, a price-to-earnings ratio of 105.25, a price-to-earnings-growth ratio of 2.26 and a beta of 1.20. DexCom has a 52 week low of $74.75 and a 52 week high of $142.00. The business’s 50 day moving average is $130.58 and its two-hundred day moving average is $117.88. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.34 earnings per share. On average, research analysts predict that DexCom will post 1.76 EPS for the current year.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the transaction, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 189,375 shares of company stock valued at $25,530,859. Corporate insiders own 0.41% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of hedge funds have recently added to or reduced their stakes in DXCM. DSM Capital Partners LLC bought a new stake in shares of DexCom in the fourth quarter valued at approximately $28,000. Valley National Advisers Inc. boosted its position in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. Riverview Trust Co bought a new stake in shares of DexCom in the first quarter valued at approximately $32,000. MV Capital Management Inc. raised its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Smithfield Trust Co raised its stake in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 165 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.